ID   HuT78B1
AC   CVCL_0325
SY   HUT78B1; HUT78-B1
DR   MCCL; MCC:0000218
DR   cancercelllines; CVCL_0325
DR   Cosmic; 2765584
DR   Wikidata; Q54896927
RX   PubMed=8598453;
RX   PubMed=15161037;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C3366; Sezary syndrome
DI   ORDO; Orphanet_3162; Sezary syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0337 ! HuT 78
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=8598453; DOI=10.4049/jimmunol.156.1.13;
RA   Cascino I., Papoff G., De Maria R., Testi R., Ruberti G.;
RT   "Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling
RT   domain protects tumor cells from Fas-mediated apoptosis.";
RL   J. Immunol. 156:13-17(1996).
//
RX   PubMed=15161037;
RA   Meli M., Tolomeo M., D'Alessandro N., Grimaudo S., Notarbartolo M.,
RA   Papoff G., Ruberti G., Rausa L., Dusonchet L.;
RT   "Resistance to gemcitabine in a lymphoma cell line resistant to
RT   Fas-mediated apoptosis.";
RL   Anticancer Res. 24:851-857(2004).
//